Voyager Therapeutics Q3 collaboration revenue drops, net loss narrows
Overview
US biotech firm's Q3 collaboration revenue fell sharply yr/yr as Neurocrine partnership shifted phases
Q3 net loss narrowed from prior year on lower R&D and administrative costs
Company ended Q3 with $132 mln in cash, expects runway into Q2 2028
Outlook
Company expects VY7523 PET imaging efficacy data in Q4 2026
Voyager anticipates dosing first VY1706 patient in the next few months, pending enrollment
Neurocrine-partnered Friedreich’s ataxia gene therapy program expected to enter clinic in coming months
Result Drivers
NEUROCRINE PARTNERSHIP SHIFT - Co said lower Q3 collaboration revenue was mainly due to reduced revenue from the Neurocrine agreement as activities moved beyond the research phase
LOWER R&D AND ADMIN COSTS - Co attributed reduced Q3 R&D and G&A expenses to lower clinical and manufacturing costs, program prioritization, and lower employee-related and consulting costs
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Collaboration Revenue | $4.01 mln | ||
Q3 Net Loss | $24.69 mln | ||
Q3 Loss Per Basic Share | $0.40 | ||
Q3 Operating Income | -$26.42 mln | ||
Q3 Pretax Loss | $24.68 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Voyager Therapeutics, Inc. is $12.00, about 541.7% above its November 4 closing price of $1.87
Reuters Recommended Reads
Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand
Nov 5 - Entrada Therapeutics Q3 net loss narrows as expenses fall
Nov 5 - Fate Therapeutics Q3 net loss narrows as expenses fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)